Article Text

Download PDFPDF

EPV084/#549 Role of dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in locally advanced cervical cancer
  1. F Multinu1,
  2. M Lapresa2,
  3. V Minicucci2,
  4. S Gandini3,
  5. G Parma2,
  6. F Peccatori4,
  7. F Tomao2,
  8. I Betella1,
  9. A Garbi1,
  10. G Schivardi1,
  11. G Aletti1,
  12. V Zanagnolo1,
  13. A Maggioni1 and
  14. N Colombo5
  1. 1IEO, European Institute of Oncology IRCSS, Division of Gynecologic Surgery, Milan, Italy
  2. 2IEO, European Institute of Oncology IRCCS, Gynecologic Oncology, Milan, Italy
  3. 3IEO, European Institute of Oncology IRCCS, Department of Experimental Oncology, Milan, Italy
  4. 4IEO, European Institute of Oncology IRCCS, Fertility and Procreation Unit, Division of Gynecologic Oncology, Milan, Italy
  5. 5University of Milan-Bicocca, European Institute of Oncology, IRCCS, Gynecologic Oncology Program, Milan, Italy


Objectives To evaluate the role of dose-dense neoadjuvant chemotherapy(NACT) with paclitaxel and carboplatin before surgery in locally advanced cervical cancer(LACC).

Methods Patients with LAAC (Stage Ib2-IVa) undergoing dose-dense NACT at the European Institute of Oncology, Milan from July 2014 to February 2019 were identified. Patients received weekly dose-dense carboplatin (AUC2 or AUC2.7) and paclitaxel (80 or 60 mg) for 6–9 cycles followed by surgery. Radiological response was evaluated by RECIST. Pathologic response was evaluated based on the final pathology report.

Results A total of 68 patients meeting inclusion criteria were included. Baseline characteristics are displayed in Table 1. According to FIGO stage(2018), the stage distribution of disease was the following: 18(26.5%) stage IB2, 28(41.2%) stage IB3, 6(8.8%) stage IIA, 6(8.8%) stage IIB, 10(14.8%) stage IIIC1. According to RECIST criteria, 6(8.8%) had complete response, 49(72.0%) partial response, 12(17.6) stable disease, 1(1.5%) progressive disease. After NACT, 13(19.1%) patients were deemed inoperable and received chemoradiation(CRT). Among the 55 (80.9%) undergoing surgery, 7(12.7%) had pathologic complete response. Due to the presence of positive lymph nodes and/or close resection margins, 17(31%) received postoperative radiotherapy. Among the remaining 37(67.3%) avoiding additional radiotherapy, during a median follow-up of 36 months(range 6–63), the recurrence rate was 13.5% (5/37).

Abstract EPV084/#549 Table 1

Baseline characteristics of the overall population (n=68)

Conclusions Dose-dense NACT achieved a good response rate. Although CRT remains the standard treatment of LACC, dose-dense NACT followed by surgery can be considered an alternative approach and allows to avoid radiotherapy in over 50% of the patients without affecting recurrence rate.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.